Cytrx Corp. shares (NASDAQ:CYTR) fell 20 percent, or 76 cents, to close at $3.04 as the cancer drug developer priced a 9.1 million share offering at $2.75 per share, a 27.6 percent discount to Monday's close. Reaction to the offering, which will raise gross proceeds of about $25 million to support pre-commercial preparations for aldoxorubicin and other programs, made Tuesday the company's second most active trading day year to date.